Cabergoline is used to treat hyperprolactinemia (high levels of prolactin, a natural substance that helps breast-feeding women produce milk but can cause symptoms such as infertility, sexual problems, and bone loss in women who are not breast-feeding or men).
Europe has the largest global export quantity and manufacturers in Cabergoline market, while the North America is the second sales volume market for Cabergoline in 2019. In the industry, Teva API profits most in 2019 and recent years, and the gap of market share is keep on enlarged due to different strategy.

Market Analysis and Insights: Global Cabergoline Market
The global Cabergoline market is valued at US$ 7 million in 2019. The market size will reach US$ 9 million by the end of 2026, growing at a CAGR of 4.8% during 2021-2026.

Global Cabergoline Scope and Market Size
Cabergoline market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cabergoline market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Purity < 95%
Purity 95%-98%
Purity > 98%
Purity 95%-98% is the main type for Cabergoline, and the Purity 95%-98% reached a sales volume of approximately 55.40 Kg in 2019, with 49.63% of global sales volume.

Segment by Application
Anti-Parkinson
Hyperprolactinemic Disorders
Others
Hyperprolactinemic Disorders is the most widely used area which took up about 71% of the global total sales in 2019.

By Company
Teva API
Finetech Pharma
Global Biologicals
Wellona Pharma
Alven Laboratories
Salvavidas Pharmaceutical

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia